Management of Ulcerative Colitis
Severe Acute Ulcerative Colitis: The Pediatric PerspectiveTurner D.
Pediatric Gastroenterology Unit, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Many features of pediatric ulcerative colitis (UC) are similar to adult-onset disease, but the rate of extensive disease is doubled in children. It is, therefore, not surprising that the admission rate for severe UC is higher in childhood-onset UC, reaching 28% by the age of 16 years. Approximately 30–40% of children will fail corticosteroids and require second-line medical therapy or colectomy. A pediatric UC activity index (PUCAI) score of >65 indicates severe disease and the index can assist in determining the need and timing of second-line medical therapy or colectomy early during the admission. A PUCAI score of >45 points on day 3 identify patients likely to fail corticosteroids (negative predictive value 90–95%), and a score >70 points on day 5 identify patients who will require short-term treatment escalation (positive predicting value 95–100%). Data in children are limited, but it seems that cyclosporine, tacrolimus and infliximab achieve a similar short-term response rate, in the range of 60–80%. Infliximab has the advantage that it may be given for a prolonged period of time while calcineurin inhibitors should not be used for more than 3–4 months, bridging to a thiopurine regimen. Colectomy is indicated in toxic megacolon or in cases refractory to one salvage therapy. The choice of colectomy in other cases should carefully consider its effect on the patient’s quality of life, its impact on the physical and emotional development at a critical age of personality development, and its association with a high infertility rate in females undergoing pouch procedure before childbearing age.
© 2009 S. Karger AG, Basel
- Truelove SC, Jewell DP: Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974;i:1067–1070.
Truelove SC, Witts LJ: Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;29:1041–1048.
- Turner D, Walsh CM, Steinhart AH, Griffiths AM: Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007;5:103–110.
- Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, et al: Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805–1811.
- Sandborn WJ: Is there a role for infliximab in the treatment of severe ulcerative colitis?: The American experience. Inflamm Bowel Dis 2008;14:S232–S233.
- Griffiths AM: Specificities of inflammatory bowel disease in childhood. Best Pract Res Clin Gastroenterol 2004;18:509–523.
- Turner D, Otley AR, Mack D, et al: Development and evaluation of a Pediatric Ulcerative Colitis Activity Index (PUCAI): a prospective multicenter study. Gastroenterology 2007;133:423–432.
- Moum B, Ekbom A, Vatn MH, Elgjo K: Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time. Am J Gastroenterol 1999;94:1564–1569.
- Hyams J, Crandall W, Kugathasan S, et al: Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology 2007;132:863–873; quiz 1165–1166.
- Hanauer SB, Feagan BG, Lichtenstein GR, et al: Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359:1541–1549.
- Markowitz J, Grancher K, Kohn N, Lesser M, Daum F: A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology 2000;119:895–902.
- Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R: A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut 1995;37:674–678.
Zachos M, Tondeur M, Griffiths AM: Enteral nutritional therapy for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2007;1:CD000542.
- Benchimol EI, Turner D, Mann EH, et al: Toxic megacolon in children with inflammatory bowel disease: clinical and radiographic characteristics. Am J Gastroenterol 2008;103:1524–1531.
- Langholz E, Munkholm P, Krasilnikoff PA, Binder V: Inflammatory bowel diseases with onset in childhood. Clinical features, morbidity, and mortality in a regional cohort. Scand J Gastroenterol 1997;32:139–147.
- Lichtiger S, Present DH: Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 1990;336:16–19.
- Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M: An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992;87:971–976.
- Lindgren SC, Flood LM, Kilander AF, Lofberg R, Persson TB, Sjodahl RI: Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998;10:831–835.
- Gulati R, Rawal KK, Kumar N, et al: Course of severe ulcerative colitis in northern India. Trop Gastroenterol 1995;16:19–23.
- Lennard-Jones JE, Ritchie JK, Hilder W, Spicer CC: Assessment of severity in colitis: a preliminary study. Gut 1975;16:579–584.
- Benazzato L, D’Inca R, Grigoletto F, et al: Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment. Dig Liver Dis 2004;36:461–466.
- Daperno M, Sostegni R, Scaglione N, et al: Outcome of a conservative approach in severe ulcerative colitis. Dig Liver Dis 2004;36:21–28.
- Spicer CC: The prediction of success or failure of medical treatment for acute colitis. J R Coll Physicians Lond 1975;9:252–256.
- Turner D, Walsh CM, Benchimol EI, et al: Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy. Gut 2008;57:331–338.
- Turner D, Hyams J, Markowitz J, et al: Appraisal of the pediatric ulcerative colitis activity index (PUCAI). Inflamm Bowel Dis 2009;15:1218–1223.
- Barabino A, Tegaldo L, Castellano E, et al: Severe attack of ulcerative colitis in children: retrospective clinical survey. Dig Liver Dis 2002;34:44–49.
- Ho GT, Mowat C, Goddard CJ, et al: Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004;19:1079–1087.
- Meyers S, Lerer PK, Feuer EJ, Johnson JW, Janowitz HD: Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results of a prospective, randomized, double-blind clinical trial. J Clin Gastroenterol 1987;9:50–54.
Jakobovits SL, Travis SP: Management of acute severe colitis. Br Med Bull 2006;75–76:131–144.
- Kugathasan S, Dubinsky MC, Keljo D, et al: Severe colitis in children. J Pediatr Gastroenterol Nutr 2005;41:375–385.
- Werlin SL, Grand RJ: Severe colitis in children and adolescents: diagnosis, course, and treatment. Gastroenterology 1977;73:828–832.
- Kornbluth A, Sachar DB: Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004;99:1371–1385.
- Travis SP, Farrant JM, Ricketts C, et al: Predicting outcome in severe ulcerative colitis. Gut 1996;38:905–910.
- Seo M, Okada M, Yao T, Matake H, Maeda K: Evaluation of the clinical course of acute attacks in patients with ulcerative colitis through the use of an activity index. J Gastroenterol 2002;37:29–34.
Turner D, Mack D, Uusoue K, et al (ed): A prospective multicenter study of outcomes and predictors of response in severe pediatric ulcerative colitis. World Congr Gastroenterol Hepatology and Nutrition, Brazil, 2008.
- Ceriati E, Deganello F, De Peppo F, et al: Surgery for ulcerative colitis in pediatric patients: functional results of 10-year follow-up with straight endorectal pull-through. Pediatr Surg Int 2004;20:573–578.
- Meagher AP, Farouk R, Dozois RR, Kelly KA, Pemberton JH: J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1,310 patients. Br J Surg 1998;85:800–803.
- Cornish JA, Tan E, Teare J, et al: The effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: a systematic review. Dis Colon Rectum 2007;50:1128–1138.
Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K: Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005;1:CD004277.
- Durai D, Hawthorne AB: Review article: how and when to use ciclosporin in ulcerative colitis. Aliment Pharmacol Ther 2005;22:907–916.
- Castro M, Papadatou B, Ceriati E, et al: Role of cyclosporin in preventing or delaying colectomy in children with severe ulcerative colitis. Langenbecks Arch Surg 2007;392:161–164.
- Barabino A, Torrente F, Castellano E, et al: The use of ciclosporin in paediatric inflammatory bowel disease: an Italian experience. Aliment Pharmacol Ther 2002;16:1503–1507.
- Ramakrishna J, Langhans N, Calenda K, Grand RJ, Verhave M: Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1996;22:296–302.
- Treem WR, Cohen J, Davis PM, Justinich CJ, Hyams JS: Cyclosporine for the treatment of fulminant ulcerative colitis in children. Immediate response, long-term results, and impact on surgery. Dis Colon Rectum 1995;38:474–479.
- Benkov KJ, Rosh JR, Schwersenz AH, Janowitz HD, LeLeiko NS: Cyclosporine as an alternative to surgery in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1994;19:290–294.
- Treem WR, Davis PM, Hyams JS: Cyclosporine treatment of severe ulcerative colitis in children. J Pediatr 1991;119:994–997.
- Kirschner BS, Whitington PF, Malfeo-Klein R: Experience with cyclosporine A (CyA) in severe non-specific ulcerative colitis. Pediatr Res 1989;25:A117.
- Ogata H, Matsui T, Nakamura M, et al: A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006;55:1255–1262.
- Ziring DA, Wu SS, Mow WS, Martin MG, Mehra M, Ament ME: Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children. J Pediatr Gastroenterol Nutr 2007;45:306–311.
- Bousvaros A, Kirschner BS, Werlin SL, et al: Oral tacrolimus treatment of severe colitis in children. J Pediatr 2000;137:794–799.
- Sternthal MB, Murphy SJ, George J, Kornbluth A, Lichtiger S, Present DH: Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease. Am J Gastroenterol 2008;103:937–943.
Lawson MM, Thomas AG, Akobeng AK: Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;3:CD005112.
- McGinnis JK, Murray KF: Infliximab for ulcerative colitis in children and adolescents. J Clin Gastroenterol 2008;42:875–879.
- Fanjiang G, Russell GH, Katz AJ: Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr 2007;44:312–317.
- Russell GH, Katz AJ: Infliximab is effective in acute but not chronic childhood ulcerative colitis. J Pediatr Gastroenterol Nutr 2004;39:166–170.
- Kugathasan S, Prajapati DN, Kim JP, et al: Infliximab outcome in children and adults with ulcerative colitis. Gastroenterology 2002;122:A615.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.